Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred


IMPACT FACTOR 2017: 3.022

CiteScore 2017: 2.81

SCImago Journal Rank (SJR) 2017: 1.562
Source Normalized Impact per Paper (SNIP) 2017: 0.705

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 399, Issue 3

Issues

TGF-β requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy

Johanna Ábrigo
  • Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas and Facultad de Medicina, Universidad Andres Bello, Avenida República 239, Santiago 8370146, Chile
  • Millennium Institute on Immunology and Immunotherapy, 8331150 Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Fabian Campos
  • Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas and Facultad de Medicina, Universidad Andres Bello, Avenida República 239, Santiago 8370146, Chile
  • Millennium Institute on Immunology and Immunotherapy, 8331150 Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Felipe Simon
  • Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas and Facultad de Medicina, Universidad Andres Bello, Avenida República 239, Santiago 8370146, Chile
  • Millennium Institute on Immunology and Immunotherapy, 8331150 Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Claudia Riedel
  • Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas and Facultad de Medicina, Universidad Andres Bello, Avenida República 239, Santiago 8370146, Chile
  • Millennium Institute on Immunology and Immunotherapy, 8331150 Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Daniel Cabrera
  • Universidad Bernardo O Higgins, Facultad de Salud, Departamento de Ciencias Químicas y Biológicas, 8370993 Santiago, Chile
  • Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Cristian Vilos
  • Laboratory of Nanomedicine and Targeted Delivery, Center for Integrative Medicine and Innovative Science, Faculty of Medicine, and Center for Bioinformatics and Integrative Biology, Faculty of Biological Sciences, Universidad Andres Bello, 8370146 Santiago, Chile
  • Center for the Development of Nanoscience and Nanotechnology (CEDENNA), Universidad de Santiago de Chile, 9170022 Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Claudio Cabello-Verrugio
  • Corresponding author
  • Millennium Institute on Immunology and Immunotherapy, 8331150 Santiago, Chile
  • Laboratory of Muscle Pathology, Fragility and Aging, Departmento de Ciencias Biológicas, Facultad de Ciencias Biológicas and Facultad de Medicina, Universidad Andres Bello, Avenida República 239, Santiago 8370146, Chile
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-11-15 | DOI: https://doi.org/10.1515/hsz-2017-0217

Abstract

The transforming growth factor type-beta (TGF-β) induces skeletal muscle atrophy characterised by a decrease in the fibre’s diameter and levels of myosin heavy chain (MHC), also as an increase of MuRF-1 expression. In addition, TGF-β induces muscle atrophy by a mechanism dependent on reactive oxygen species (ROS). TGF-β signals by activating both canonical Smad-dependent, and non-canonical signalling pathways such as ERK1/2, JNK1/2, and p38 MAPKs. However, the participation of canonical and non-canonical signalling pathways in the TGF-β atrophic effect on skeletal muscle is unknown. We evaluate the impact of Smad and MAPK signalling pathways on the TGF-β-induced atrophic effect in C2C12 myotubes. The results indicate that TGF-β activates Smad2/3, ERK1/2 and JNK1/2, but not p38 in myotubes. The pharmacological inhibition of Smad3, ERK1/2 and JNK1/2 activation completely abolished the atrophic effect of TGF-β. Finally, the inhibition of these canonical and non-canonical pathways did not decrease the ROS increment, while the inhibition of ROS production entirely abolished the phosphorylation of Smad3, ERK1/2 and JNK1/2. These results suggest that TGF-β requires Smad3, ERK1/2 and JNK1/2 activation to produce skeletal muscle atrophy. Moreover, the induction of ROS by TGF-β is an upstream event to canonical and non-canonical pathways.

This article offers supplementary material which is provided at the end of the article.

Keywords: MAPK; MuRF-1; muscle atrophy; reactive oxygen species; Smad

References

  • Abrigo, J., Morales, M.G., Simon, F., Cabrera, D., Di Capua, G., and Cabello-Verrugio, C. (2015). Apocynin inhibits the upregulation of TGF-β1 expression and ROS production induced by TGF-beta in skeletal muscle cells. Phytomedicine 22, 885–93.Web of ScienceCrossrefPubMedGoogle Scholar

  • Abrigo, J., Rivera, J.C., Simon, F., Cabrera, D., and Cabello-Verrugio, C. (2016). Transforming growth factor type β (TGF-β) requires reactive oxygen species to induce skeletal muscle atrophy. Cell Signal. 28, 366–376.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Acuna, M.J., Pessina, P., Olguin, H., Cabrera, D., Vio, C.P., Bader, M., Munoz-Canoves, P., Santos, R.A., Cabello-Verrugio, C., and Brandan, E. (2014). Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling. Hum. Mol. Genet. 23, 1237–1249.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Argiles, J.M., Busquets, S., Felipe, A., and Lopez-Soriano, F.J. (2006). Muscle wasting in cancer and ageing: cachexia versus sarcopenia. Adv. Gerontol. 18, 39–54.PubMedGoogle Scholar

  • Barbieri, E. and Sestili, P. (2012). Reactive oxygen species in skeletal muscle signaling. J. Signal. Transduct. 2012, 982794.PubMedGoogle Scholar

  • Bennett, B.L., Sasaki, D.T., Murray, B.W., O’Leary, E.C., Sakata, S.T., Xu, W., Leisten, J.C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98, 13681–13686.CrossrefGoogle Scholar

  • Bernasconi, P., Di Blasi, C., Mora, M., Morandi, L., Galbiati, S., Confalonieri, P., Cornelio, F., and Mantegazza, R. (1999). Transforming growth factor-β1 and fibrosis in congenital muscular dystrophies. Neuromuscul. Disord. 9, 28–33.PubMedCrossrefGoogle Scholar

  • Brandan, E., Cabello-Verrugio, C., and Vial, C. (2008). Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol. 27, 700–708.Web of SciencePubMedCrossrefGoogle Scholar

  • Brink, M., Price, S.R., Chrast, J., Bailey, J.L., Anwar, A., Mitch, W.E., and Delafontaine, P. (2001). Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142, 1489–1496.PubMedCrossrefGoogle Scholar

  • Burks, T.N. and Cohn, R.D. (2011). Role of TGF-beta signaling in inherited and acquired myopathies. Skelet. Muscle 1, 19.PubMedCrossrefWeb of ScienceGoogle Scholar

  • Burks, T.N., Andres-Mateos, E., Marx, R., Mejias, R., Van Erp, C., Simmers, J.L., Walston, J.D., Ward, C.W., and Cohn, R.D. (2011). Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med. 3, 82ra37.Web of SciencePubMedGoogle Scholar

  • Cabello-Verrugio, C. and Brandan, E. (2007). A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J. Biol. Chem. 282, 18842–18850.CrossrefPubMedGoogle Scholar

  • Cabello-Verrugio, C., Acuna, M.J., Morales, M.G., Becerra, A., Simon, F., and Brandan, E. (2011). Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells. Biochem. Biophys. Res. Commun. 410, 665–670.Web of ScienceCrossrefGoogle Scholar

  • Cabello-Verrugio, C., Cordova, G., and Salas, J.D. (2012a). Angiotensin II: role in skeletal muscle atrophy. Curr. Protein Pept. Sci. 13, 560–569.CrossrefWeb of ScienceGoogle Scholar

  • Cabello-Verrugio, C., Santander, C., Cofre, C., Acuna, M.J., Melo, F., and Brandan, E. (2012b). The internal region leucine-rich repeat 6 of decorin interacts with low density lipoprotein receptor-related protein-1, modulates transforming growth factor (TGF)-β-dependent signaling, and inhibits TGF-β-dependent fibrotic response in skeletal muscles. J. Biol. Chem. 287, 6773–6787.CrossrefWeb of ScienceGoogle Scholar

  • Cabello-Verrugio, C., Morales, M.G., Rivera, J.C., Cabrera, D., and Simon, F. (2015). Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med. Res. Rev. 35, 437–463.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Cencetti, F., Bernacchioni, C., Nincheri, P., Donati, C., and Bruni, P. (2010). Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol. Biol. Cell. 21, 1111–1124.CrossrefPubMedGoogle Scholar

  • Chomczynski, P. and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159.PubMedGoogle Scholar

  • Cofre, C., Acuna, M.J., Contreras, O., Morales, M.G., Riquelme, C., Cabello-Verrugio, C., and Brandan, E. (2015). Transforming growth factor type-beta inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies. Biofactors 41, 111–120.PubMedCrossrefWeb of ScienceGoogle Scholar

  • Cooney, R.N., Kimball, S.R., and Vary, T.C. (1997). Regulation of skeletal muscle protein turnover during sepsis: mechanisms and mediators. Shock 7, 1–16.CrossrefPubMedGoogle Scholar

  • Derynck, R. and Zhang, Y.E. (2003). Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577–584.PubMedCrossrefGoogle Scholar

  • Droguett, R., Cabello-Verrugio, C., Santander, C., and Brandan, E. (2010). TGF-β receptors, in a Smad-independent manner, are required for terminal skeletal muscle differentiation. Exp. Cell Res. 316, 2487–2503.CrossrefWeb of ScienceGoogle Scholar

  • Eley, H.L., Russell, S.T., and Tisdale, M.J. (2008). Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-α and angiotensin II by β-hydroxy-β-methylbutyrate. Am. J. Physiol. Endocrinol. Metab. 295, E1417–E1426.Google Scholar

  • Evans, W.J., Morley, J.E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., et al. (2008). Cachexia: a new definition. Clin. Nutr. 27, 793–799.PubMedWeb of ScienceCrossrefGoogle Scholar

  • Glass, D.J. (2005). Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984.CrossrefPubMedGoogle Scholar

  • Greco, S.H., Tomkotter, L., Vahle, A.K., Rokosh, R., Avanzi, A., Mahmood, S.K., Deutsch, M., Alothman, S., Alqunaibit, D., Ochi, A., et al. (2015). TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One 10, e0132786.Web of ScienceCrossrefGoogle Scholar

  • Guadagnin, E., Narola, J., Bonnemann, C.G., and Chen, Y.W. (2015). Tyrosine 705 phosphorylation of STAT3 is associated with phenotype severity in TGFβ1 transgenic mice. Biomed. Res. Int. 2015, 843743.PubMedWeb of ScienceGoogle Scholar

  • Huang, Z., Chen, D., Zhang, K., Yu, B., Chen, X., and Meng, J. (2007). Regulation of myostatin signaling by c-Jun N-terminal kinase in C2C12 cells. Cell Signal. 19, 2286–2295.PubMedWeb of ScienceCrossrefGoogle Scholar

  • Ishitobi, M., Haginoya, K., Zhao, Y., Ohnuma, A., Minato, J., Yanagisawa, T., Tanabu, M., Kikuchi, M., and Iinuma, K. (2000). Elevated plasma levels of transforming growth factor β1 in patients with muscular dystrophy. Neuroreport 11, 4033–4035.PubMedGoogle Scholar

  • Jackman, R.W. and Kandarian, S.C. (2004). The molecular basis of skeletal muscle atrophy. Am J. Physiol. Cell Physiol. 287, C834–843.CrossrefPubMedGoogle Scholar

  • Kefaloyianni, E., Gaitanaki, C., and Beis, I. (2006). ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-κB transactivation during oxidative stress in skeletal myoblasts. Cell Signal. 18, 2238–2251.CrossrefPubMedGoogle Scholar

  • Kollias, H.D. and McDermott, J.C. (2008). Transforming growth factor-β and myostatin signaling in skeletal muscle. J. Appl. Physiol. 104, 579–587.Web of ScienceCrossrefPubMedGoogle Scholar

  • Massague, J. (2012). TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616–630.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Mauro, A., Ciccarelli, C., De Cesaris, P., Scoglio, A., Bouche, M., Molinaro, M., Aquino, A., and Zani, B.M. (2002). PKCα-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J. Cell Sci. 115, 3587–3599.PubMedCrossrefGoogle Scholar

  • Mendias, C.L., Gumucio, J.P., Davis, M.E., Bromley, C.W., Davis, C.S., and Brooks, S.V. (2012). Transforming growth factor-β induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 45, 55–59.Web of ScienceCrossrefPubMedGoogle Scholar

  • Meneses, C., Morales, M.G., Abrigo, J., Simon, F., Brandan, E., and Cabello-Verrugio, C. (2015). The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice. Pflüger’s Arch. 467, 1975–1984.CrossrefGoogle Scholar

  • Miro, O., Pedrol, E., Cebrian, M., Masanes, F., Casademont, J., Mallolas, J., and Grau, J.M. (1997). Skeletal muscle studies in patients with HIV-related wasting syndrome. J. Neurol. Sci. 150, 153–159.PubMedCrossrefGoogle Scholar

  • Morales, M.G., Vazquez, Y., Acuna, M.J., Rivera, J.C., Simon, F., Salas, J.D., Alvarez Ruf, J., Brandan, E., and Cabello-Verrugio, C. (2012). Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor β1 expression in skeletal muscle cells. Int. J. Biochem. Cell Biol. 44, 1993–2002.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Morales, M.G., Abrigo, J., Meneses, C., Simon, F., Cisternas, F., Rivera, J.C., Vazquez, Y., and Cabello-Verrugio, C. (2014). The Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of TGF-β1 induced by AngII in mouse skeletal muscle. Clin. Sci. 127, 251–264.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Morris, R.T., Spangenburg, E.E., and Booth, F.W. (2004). Responsiveness of cell signaling pathways during the failed 15-day regrowth of aged skeletal muscle. J. Appl. Physiol. 96, 398–404.CrossrefPubMedGoogle Scholar

  • Narola, J., Pandey, S.N., Glick, A., and Chen, Y.W. (2013). Conditional expression of TGF-β1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One 8, e79356.Web of SciencePubMedCrossrefGoogle Scholar

  • Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., and Sandri, M. (2009). Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 296, C1248–C1257.Web of ScienceGoogle Scholar

  • Schmittgen, T.D., Zakrajsek, B.A., Mills, A.G., Gorn, V., Singer, M.J., and Reed, M.W. (2000). Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal. Biochem. 285, 194–204.CrossrefPubMedGoogle Scholar

  • Tando, T., Hirayama, A., Furukawa, M., Sato, Y., Kobayashi, T., Funayama, A., Kanaji, A., Hao, W., Watanabe, R., Morita, M., et al. (2016). Smad2/3 are required for immobilization-induced skeletal muscle atrophy. J. Biol. Chem. 291, 12184–12194.Web of SciencePubMedCrossrefGoogle Scholar

  • ten Dijke, P. and Hill, C.S. (2004). New insights into TGF-β-Smad signalling. Trends Biochem. Sci. 29, 265–273.PubMedCrossrefGoogle Scholar

  • Tisdale, M.J. (2009). Mechanisms of cancer cachexia. Physiol. Rev. 89, 381–410.Web of ScienceCrossrefPubMedGoogle Scholar

  • Trendelenburg, A.U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., and Glass, D.J. (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296, C1258–C1270.Web of ScienceGoogle Scholar

  • Winer, J., Jung, C.K., Shackel, I., and Williams, P.M. (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270, 41–49.CrossrefPubMedGoogle Scholar

  • Zhang, P., Chen, X., and Fan, M. (2007). Signaling mechanisms involved in disuse muscle atrophy. Med. Hypotheses 6, 310–321.Web of ScienceGoogle Scholar

About the article

Received: 2017-08-11

Accepted: 2017-11-03

Published Online: 2017-11-15

Published in Print: 2018-02-23


Citation Information: Biological Chemistry, Volume 399, Issue 3, Pages 253–264, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/hsz-2017-0217.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Mahadevan R. Rajasekaran, Johnny Fu, My-Uyen Lilly Nguyen, Yaozhi Wang, Michael Albo, and Valmik Bhargava
Neurourology and Urodynamics, 2018
[2]
Xiaofan Yang, Pingping Xue, Xin Liu, Xiang Xu, and Zhenbing Chen
Cell Communication and Signaling, 2018, Volume 16, Number 1
[3]
He-He Hu, Dan-Qian Chen, Yan-Ni Wang, Ya-Long Feng, Gang Cao, Nosratola D. Vaziri, and Ying-Yong Zhao
Chemico-Biological Interactions, 2018

Comments (0)

Please log in or register to comment.
Log in